Future studies will shed light on whether TAK1 or IKKα/β inhibitors can exacerbate AD phenotypes in APP/PS1 mice and whether pro-inflammatory pathways upstream of TAK1-IKKα/β signaling play a role in the pathogenesis of AD. This evidence concerns the gene CHUK and Alzheimer disease.